TRACON Pharmaceuticals, Inc. (TCON)

Market Cap	707.07K
Revenue (ttm)	3.20M
Net Income (ttm)	5.20M
Shares Out	3.41M
EPS (ttm)	2.27
PE Ratio	0.09
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	51,426
Open	0.190
Previous Close	0.150
Day's Range	0.160 - 0.200
52-Week Range	0.002 - 14.750
Beta	1.35
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 8, 2024

About TRACON Pharmaceuticals

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications. The company’s clinical stage products also in...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 17
• Stock Exchange: OTCMKTS
• Ticker Symbol: TCON